Last updated on April 2018

Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases HRQoL and Comparison of Imaging Techniques


Brief description of study

Prospective observational study to assess bone predictive biomarkers for TKI response in RCC patients with bone metastasis and HRQoL with TKI in these patients as well as the sensitivity and specificity of whole body magnetic resonance versus bone scintigraphy and versus CT in the assessment of metastatic lesions at bone level and at other sites.

Detailed Study Description

Prospective observational study to assess:

  • Bone predictive biomarkers for tyrosine kinase inhibitor (TKI) response in renal cell carcinoma (RCC) patients with bone metastasis - Health Related Quality of Life (HRQoL) with TKI
  • Comparison of the sensitivity and specificity of whole body magnetic resonance versus bone scintigraphy and versus Computerized tomography (CT) in the assessment of metastatic lesions at bone level and at other sites.

Clinical Study Identifier: NCT02747173

Contact Investigators or Research Sites near you

Start Over

Serafin Costilla, MD

Hospital Universitario central de Asturias
Oviedo, Spain

Roberto Garcia, MD

Complejo Hospitalario Univ de Santiago de Compostela
Santiago de Compostela, Spain

Carmen Sanchez, MD

Hospital de Navarra
Pamplona, Spain

Mercedes Arias, MD

Complejo Hospitalario Univ de Vigo
Vigo, Spain

Rafael Valls, MD

Consorcio Hospitalario Parc Tauli
Barcelona, Spain

Raquel Rueda, MD

Complejo Hospitalario de Le n
Leon, Spain

Sergio Vazquez, MD

Hospital Univ Lucus Augusti
Lugo, Spain

Ovidio Fernández

Complejo Hospitalario de Ourense
Ourense, Spain

Paula Pelechano, MD

Instituto Valenciano de Oncologia
Valencia, Spain

Isabel Elia, MD

Hospital Universitario La Fe
Valencia, Spain

Luis Sarria, MD

Hospital Miguel Servet
Zaragoza, Spain

Amaia Arrillaga, MD

Hospital de Donostia
San Sebastián, Spain